hVIVO plc is the name of our LSE AIM-listed business, which was re-named and re-branded from Retroscreen Virology Group plc on 15th April 2015.

‘hVIVO’ and ‘FluCamp’ are registered trademarks of hVIVO Services Limited.

Retroscreen Virology was originally incorporated in 1988 as a spin-out company from Queen Mary, University of London, to commercialise the academic research of Professor John Oxford in the field of retroviruses, which at the time, were considered to have promise in the fight against HIV/Aids.

In 2001, Professor Oxford was asked to expand from the laboratory and leverage his early career experience in these early Human Viral Challenge Studies. Studies were conducted at Retroscreen Virology, led by Dr Robert Lambkin-Williams and Dr Anthony Gilbert, to develop a series of well-characterised virus stocks whilst demonstrating that the Human Viral Challenge Model could be effective in offering clients a faster and cost effective route to market for their therapeutics. One notable study was the first proof of the efficacy of a siRNA therapeutic, in which Retroscreen Virology’s Human Viral Challenge Model proved instrumental.

With the Human Viral Challenge Model gaining acceptance in an increasing number of peer-reviewed publications, Retroscreen Virology as was, designed and built its own dedicated, bespoke quarantine unit in London, which opened in early 2011. Since this time, the scientific and medical teams have expanded substantially, and between them, have significant experience of designing and conducting Human Viral Challenge Model studies.